fbpx
X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

PacBio Announces Third Quarter 2021 Financial Results

Tuesday, November 2, 2021

MENLO PARK, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2021.

Record revenue reflects 6th straight quarter of sequential growth

  • Revenue of $34.9 million, an 83% increase compared with $19.1 million in the prior year period.
  • Placed 44 Sequel II/IIe systems during the quarter compared to 20 Sequel II systems placed in the prior year quarter and 38 Sequel II/IIe systems placed in the second quarter of 2021.
  • Installed base of 326 Sequel II/IIe systems as of September 30, 2021, compared with 168 as of September 30, 2020.
  • Instrument revenue of $15.9 million, compared with $7.7 million in the prior year period.
  • Consumables revenue of $14.6 million compared with $8.0 million in the prior year period.
  • Service and other revenue of $4.4 million compared with $3.3 million in the prior year period.

Gross profit for the third quarter of 2021 was $15.4 million, representing a 117% increase compared with $7.1 million for the third quarter of 2020 and gross margin of 44% in the period compared to 37% for the third quarter of 2020. Excluding merger-related fair value inventory adjustments and amortization of intangible assets, non-GAAP gross profit for the third quarter of 2021 was $15.7 million and represented a non-GAAP gross margin of 45% in the third quarter of 2021, compared to 37% for the third quarter of 2020.

Operating expenses totaled $89.8 million for the third quarter of 2021, compared to $31.2 million for the third quarter of 2020. Excluding merger-related expenses and amortization of intangible assets, non-GAAP operating expenses totaled $59.1 million for the third quarter of 2021, compared to $31.2 million for the third quarter of 2020. Operating expenses for the third quarter of 2021 and the third quarter of 2020 included non-cash stock-based compensation of $26.6 million and $4.3 million, respectively. Excluding merger-related expenses, operating expenses in the third quarter of 2021 included $15.1 million of non-cash stock-based compensation.

Net income for the third quarter of 2021 was $16.5 million, compared to a net loss of $23.7 million for the third quarter of 2020. Excluding merger-related expenses, an income tax benefit resulting from the acquisitions of Omniome and Circulomics, fair value inventory adjustments, and amortization of intangible assets, non-GAAP net loss for the third quarter of 2021 was $47.2 million, compared to $23.7 million for the third quarter of 2020.

Basic and diluted net income per share for the third quarter of 2021 was $0.08 compared to net loss per share of $0.14 for the third quarter of 2020. Non-GAAP net loss per share for the third quarter of 2021 was $0.23 compared to $0.14 for the third quarter of 2020.

Cash, cash equivalents and investments, excluding short and long-term restricted cash, at September 30, 2021, totaled $1,079.9 million, compared to $318.8 million at December 31, 2020.

Updates since our last earnings release

  • Closed previously announced acquisition of Omniome, which adds a highly differentiated short-read sequencing technology capable of delivering increased sequencing accuracy and establishes a San Diego presence
  • Completed a $300 million PIPE financing in support of Omniome acquisition from a premier syndicate of life sciences investors
  • Partnered with the European Reference Genome Atlas (ERGA) consortium to support its efforts in understanding and protecting biodiversity by generating high-quality reference genomes for European plant and animal species
  • Announced Prenetics Group Limited, a leading global genomics and diagnostic testing company, will use PacBio HiFi sequencing for its comprehensive genetic screening services outside of the United States
  • Sequel II became PacBio’s first regulatory approved instrument as Berry Genomics announced it obtained China NMPA approval for the system and related reagents

“Our focus on execution enabled us to achieve another record quarter, highlighted by Sequel II/IIe installations at an all-time high,” said Christian Henry, President and Chief Executive Officer. “We continue to build momentum, and we are just beginning to see the tangible results from our investments in the business. With approximately 700 global employees, an expanding commercial presence, and groundbreaking short- and long-read products in development, PacBio is in prime position to deliver on its mission to enable the promise of genomics to better human health.”

Impact of COVID-19 Pandemic

Financial results for the third quarter of 2020 were negatively impacted as multiple customers postponed system deliveries, and the financial results for much of 2020 were further impacted as several customers shut down or limited operations for various periods to help curb the spread of the COVID-19 pandemic. Instrument utilization largely returned to normal by the fourth quarter of 2020, and we subsequently have not seen significant issues with deliveries or operations at customer sites. This resulted in higher product revenues of $30.5 million for the third quarter of 2021 compared to $15.7 million for the same period of 2020. Uncertainties associated with the pandemic, including recent resurgences in infection rates, may cause further impacts to our operations and financial results.

Quarterly Conference Call Information

Management will host a quarterly conference call to discuss its third quarter ended September 30, 2021, results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330, using Conference ID # 5129207. The call will be webcast live and will be available for replay at PacBio’s website at https://investor.pacificbiosciences.com/.

About PacBio

Pacific Biosciences of California, Inc. (NASDAQ: PACB), is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.

Statement regarding use of non‐GAAP financial measures

The company reports non‐GAAP results for basic and diluted net income and loss per share, net income, net loss, gross margins, gross profit and operating expenses in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company’s financial measures under GAAP include substantial charges such as merger related expenses, and others that are listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. The amortization of intangible assets excluded from GAAP financial measures relates to acquired intangible assets that were recorded as part of the purchase accounting this quarter. Such intangible assets contribute to revenue generation and its amortization will recur in future periods until they are fully amortized. Management has excluded the effects of these items in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance. In addition, management uses non-GAAP measures to compare our performance relative to forecasts and strategic plans and to benchmark our performance externally against competitors.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non‐GAAP results are presented in the tables of this release.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to potential increased accuracy of short-read sequencing technology; collaboration efforts, including in connection with establishing reference genomes; potential use of PacBio products and technology by Prenetics Group Limited in its genetic screening products and services; and expectations regarding PacBio’s momentum, potential expansion of commercial presence, capabilities and development of short- and long-read products and technology, position and ability to enable genomics and better human health, and business investments. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond PacBio’s control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in PacBio’s most recent filings with the Securities and Exchange Commission, including PacBio’s most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” PacBio undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

The condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in PacBio’s Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission.

Contacts

Investors:
Todd Friedman
650.521.8450
ir@pacificbiosciences.com

Media:
Kathy Lynch
pr@pacificbiosciences.com



Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(in thousands, except per share amounts)

                 
  Three Months Ended
  September 30, 2021   June 30, 2021   September 30, 2020
Revenue:                
Product revenue $ 30,502     $ 26,533     $ 15,749  
Service and other revenue   4,385       4,077       3,333  
Total revenue   34,887       30,610       19,082  
Cost of revenue:                
Cost of product revenue   15,530       13,222       9,228  
Cost of service and other revenue   3,870       3,635       2,790  
Amortization of intangible assets   123              
Total cost of revenue   19,523       16,857       12,018  
Gross profit   15,364       13,753       7,064  
Operating expense:                
Research and development   27,508       22,266       16,467  
Sales, general and administrative   31,606       29,060       14,772  
Merger-related expenses (1)   30,726              
Total operating expense   89,840       51,326       31,239  
                 
Operating loss   (74,476 )     (37,573 )     (24,175 )
Interest expense   (3,673 )     (3,589 )      
Other income (expense), net   (133 )     161       467  
Loss before benefit from income taxes   (78,282 )     (41,001 )     (23,708 )
Benefit from income taxes (2)   (94,824 )            
Net income (loss) $ 16,542     $ (41,001 )   $ (23,708 )
                 
Net income (loss) per share:                
Basic $ 0.08     $ (0.21 )   $ (0.14 )
Diluted $ 0.08     $ (0.21 )   $ (0.14 )
                 
Shares used in computing net income (loss) per share:                
Basic   202,194       198,568       166,862  
Diluted   215,127       198,568       166,862  

__________

(1)   Merger-related expenses for the three months ended September 30, 2021 consist of $11.8 million of transaction costs arising from the acquisitions of Omniome and Circulomics and $18.9 million of stock-based compensation expense resulting from the acceleration of certain equity awards in connection with the Omniome merger.

(2)   A deferred income tax benefit of $94.8 million for the three months ended September 30, 2021, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions.



Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(in thousands, except per share amounts)

                       
                       
  Three Months Ended September 30,   Nine Months Ended September 30,
  2021
  2020
  2021
  2020
Revenue:                      
Product revenue $ 30,502     $ 15,749     $ 82,338     $ 41,798  
Service and other revenue   4,385       3,333       12,156       9,959  
Total revenue   34,887       19,082       94,494       51,757  
Cost of revenue:                      
Cost of product revenue   15,530       9,228       41,449       22,874  
Cost of service and other revenue   3,870       2,790       10,828       7,718  
Amortization of intangible assets   123             123        
Total cost of revenue   19,523       12,018       52,400       30,592  
Gross profit   15,364       7,064       42,094       21,165  
Operating expense:                      
Research and development   27,508       16,467       70,323       46,727  
Sales, general and administrative   31,606       14,772       86,804       54,846  
Merger-related expenses (1)   30,726             30,726        
Total operating expense   89,840       31,239       187,853       101,573  
                       
Operating loss   (74,476 )     (24,175 )     (145,759 )     (80,408 )
Gain (loss) from Continuation Advances from Illumina               (52,000 )     34,000  
Interest expense   (3,673 )           (9,051 )     (267 )
Other income (expense), net   (133 )     467       92       1,143  
Loss before benefit from income taxes   (78,282 )     (23,708 )     (206,718 )     (45,532 )
Benefit from income taxes (2)   (94,824 )           (94,824 )      
Net income (loss) $ 16,542     $ (23,708 )   $ (111,894 )   $ (45,532 )
                       
Net income (loss) per share:                      
Basic $ 0.08     $ (0.14 )   $ (0.56 )   $ (0.29 )
Diluted $ 0.08     $ (0.14 )   $ (0.56 )   $ (0.29 )
                       
Shares used in computing net income (loss) per share:                      
Basic   202,194       166,862       198,545       158,195  
Diluted   215,127       166,862       198,545       158,195  

__________

(1)   Merger-related expenses for the three months and nine months ended September 30, 2021 consist of $11.8 million of transaction costs arising from the acquisitions of Omniome and Circulomics and $18.9 million of stock-based compensation expense resulting from the acceleration of certain equity awards in connection with the Omniome merger.

(2)   A deferred income tax benefit of $94.8 million for the three months and nine months ended September 30, 2021, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions.


Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(in thousands)

           
  September 30,   December 31,
  2021   2020
Assets      
Cash and investments $ 1,079,890   $ 318,814
Accounts receivable   23,946     16,837
Inventory   18,276     14,230
Prepaid and other current assets   7,193     4,870
Property and equipment, net   31,119     24,899
Operating lease right-of-use assets, net   45,862     29,951
Restricted cash   5,060     4,336
Intangible assets, net   411,206    
Goodwill   411,533    
Other long-term assets   70     43
Total Assets $ 2,034,155   $ 413,980
           
Liabilities and Stockholders’ Equity          
Accounts payable $ 4,960   $ 3,579
Accrued expenses   30,820     17,350
Deferred revenue   28,220     10,290
Operating lease liabilities   57,082     41,999
Contingent consideration liability   168,574    
Convertible senior notes, net   895,915    
Other liabilities   7,777     5,271
Stockholders’ equity   840,807     335,491
Total Liabilities and Stockholders’ Equity $ 2,034,155   $ 413,980



Pacific Biosciences of California, Inc.
Reconciliation of Non-GAAP Financial Measures
(in thousands, except per share amounts)

                             
  Three Months Ended   Nine Months Ended
  September 30,   June 30,   September 30,   September 30,   September 30,
  2021   2021   2020   2021   2020
                             
GAAP net income (loss) $ 16,542     $ (41,001 )   $ (23,708 )   $ (111,894 )   $ (45,532 )
Merger-related expenses (1)   30,726                   30,726        
Income tax benefit resulting from acquisitions (2)   (94,824 )                 (94,824 )      
Fair value adjustment to Circulomics inventory at acquisition date   183                   183        
Amortization of intangible assets   154                   154        
Loss (gain) from Continuation Advances from Illumina                     52,000       (34,000 )
Non-GAAP net loss $ (47,219 )   $ (41,001 )   $ (23,708 )   $ (123,655 )   $ (79,532 )
                             
GAAP net income (loss) per share – diluted $ 0.08     $ (0.21 )   $ (0.14 )   $ (0.56 )   $ (0.29 )
Merger-related expenses (1)   0.15                   0.15        
Income tax benefit resulting from acquisitions (2)   (0.47 )                 (0.48 )      
Loss (gain) from Continuation Advances from Illumina                     0.26       (0.21 )
Other adjustments and rounding differences   0.01                   0.01        
Non-GAAP net loss per share – diluted $ (0.23 )   $ (0.21 )   $ (0.14 )   $ (0.62 )   $ (0.50 )
                             
GAAP gross profit $ 15,364     $ 13,753     $ 7,064     $ 42,094     $ 21,165  
Fair value adjustment to Circulomics inventory at acquisition date   183                   183        
Amortization of intangible assets   123                   123        
Non-GAAP gross profit $ 15,670     $ 13,753     $ 7,064     $ 42,400     $ 21,165  
                             
GAAP total operating expense $ 89,840     $ 51,326     $ 31,239     $ 187,853     $ 101,573  
Merger-related expenses (1)   (30,726 )                 (30,726 )      
Amortization of intangible assets   (31 )                 (31 )      
Non-GAAP total operating expense $ 59,083     $ 51,326     $ 31,239     $ 157,096     $ 101,573  

__________

(1)   Merger-related expenses for the three months and nine months ended September 30, 2021 consist of $11.8 million of transaction costs arising from the acquisitions of Omniome and Circulomics and $18.9 million of stock-based compensation expense resulting from the acceleration of certain equity awards in connection with the Omniome merger.

(2)   A deferred income tax benefit of $94.8 million for the three months and nine months ended September 30, 2021, is related to the release of the valuation allowance for deferred tax assets due to the recognition of deferred tax liabilities in connection with the Omniome and Circulomics acquisitions.

Press Release

PacBio Grants Equity Incentive Award to New Employee

Friday, December 3, 2021

Stay
Current

Visit our blog »